ImmuPharma Balance Sheet Health
Financial Health criteria checks 4/6
ImmuPharma has a total shareholder equity of £1.7M and total debt of £0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are £3.3M and £1.6M respectively.
Key information
0%
Debt to equity ratio
UK£0
Debt
Interest coverage ratio | n/a |
Cash | UK£210.58k |
Equity | UK£1.74m |
Total liabilities | UK£1.55m |
Total assets | UK£3.29m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 25I's short term assets (£1.8M) exceed its short term liabilities (£1.6M).
Long Term Liabilities: 25I has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: 25I is debt free.
Reducing Debt: 25I has no debt compared to 5 years ago when its debt to equity ratio was 2%.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Insufficient data to determine if 25I has enough cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if 25I has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.